Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.


A multicenter, randomized double blind phase 3 study of sunitinib in metastatic colorectal cancer patients receiving irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) as first line treatment

Unique Dataset IDNCT00457691
SponsorPfizerData ProviderPfizerTotal Study Enrolled Patients768Comparator (Control) Arm Enrolled Patients382RandomizationYes
Study PhaseClinical Study Phase IIIBlinding MethodDouble-BlindedType(s) of dataOnly comparator arm dataIntervention TypeChemotherapy, DrugDataset TypeOther

Clinical Trial Title

A multicenter, randomized double blind phase 3 study of sunitinib in metastatic colorectal cancer patients receiving irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) as first line treatment

Trial Summary and Conditions

This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in previously untreated metastatic colorectal cancer

Data Summary

Following a second prespecified interim analysis, the study was stopped because of potential futility of sunitinib plus FOLFIRI. Final results are reported. The PFS hazard ratio was 1.095 (95% CI, 0.892 to 1.344; one-sided stratified log-rank P = .807), indicating a lack of superiority for sunitinib plus FOLFIRI. Median PFS for the sunitinib arm was 7.8 months (95% CI, 7.1 to 8.4 months) versus 8.4 months (95% CI, 7.6 to 9.2 months) for the placebo arm. Sunitinib plus FOLFIRI was associated with more grade ?? 3 adverse events and laboratory abnormalities than placebo (especially diarrhea, stomatitis/oral syndromes, fatigue, hand-foot syndrome, neutropenia, thrombocytopenia, anemia, and febrile neutropenia). More deaths as a result of toxicity (12 v four) and significantly more dose delays, dose reductions, and treatment discontinuations occurred in the sunitinib arm.

Study Objectives

This study was a prospective, multicenter, randomized (1:1), double-blind, placebo-controlled, parallel-arm, Phase 3 clinical trial to evaluate the efficacy and safety of sunitinib versus placebo in metastatic colorectal cancer patients receiving FOLFIRI (irinotecan, 5-FU and leucovorin) in the first-line treatment setting. Only patients for whom FOLFIRI was clinically indicated and have not been previously treated for metastatic disease were eligible to participate.

Outcome Measures

PFS, RR, safety

Available Downloads:

To gain access to the data and analytic tools click here.

PROTOCOL: A6181122 Final Protocol 28 AUGUST 2007_1.pdf

CRF: A6181122 Case Report Form.pdf


DATA (COMPARATOR ARM): adverse.sas7bdat

DATA (COMPARATOR ARM): cd_b_p.sas7bdat

DATA (COMPARATOR ARM): cn_6_p.sas7bdat

DATA (COMPARATOR ARM): cn_7_p.sas7bdat

DATA (COMPARATOR ARM): cn_8_p.sas7bdat

DATA (COMPARATOR ARM): condrug.sas7bdat

DATA (COMPARATOR ARM): contrt.sas7bdat

DATA (COMPARATOR ARM): demog.sas7bdat

DATA (COMPARATOR ARM): ecg.sas7bdat

DATA (COMPARATOR ARM): final.sas7bdat

DATA (COMPARATOR ARM): iota_p.sas7bdat

DATA (COMPARATOR ARM): lab_safe.sas7bdat

DATA (COMPARATOR ARM): pfm_p.sas7bdat

DATA (COMPARATOR ARM): phyexam.sas7bdat

DATA (COMPARATOR ARM): prevdis.sas7bdat

DATA (COMPARATOR ARM): primdiag.sas7bdat

DATA (COMPARATOR ARM): random.sas7bdat

DATA (COMPARATOR ARM): testdrug.sas7bdat

DATA (COMPARATOR ARM): tmm_p.sas7bdat

DATA (COMPARATOR ARM): vitals.sas7bdat